Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Cash from Financing Activities (2019 - 2025)

Quantum Biopharma's Cash from Financing Activities history spans 5 years, with the latest figure at $1.4 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 42.68% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.1 million, a 47.51% decrease, with the full-year FY2025 number at $6.1 million, down 47.51% from a year prior.
  • Cash from Financing Activities hit $1.4 million in Q4 2025 for Quantum Biopharma, up from $261425.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for QNTM hit a ceiling of $6.7 million in Q3 2024 and a floor of -$4.1 million in Q4 2022.
  • Historically, Cash from Financing Activities has averaged $1.3 million across 3 years, with a median of $1.4 million in 2025.
  • The widest YoY moves for Cash from Financing Activities: up 450.97% in 2025, down 96.12% in 2025.
  • Tracing QNTM's Cash from Financing Activities over 3 years: stood at -$4.1 million in 2022, then skyrocketed by 160.34% to $2.5 million in 2024, then plummeted by 42.68% to $1.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for QNTM at $1.4 million in Q4 2025, $261425.0 in Q3 2025, and $1.3 million in Q2 2025.